普瑞巴林在脑卒中后中枢神经痛治疗中的观察研究

Observation and analysis of pregabalin in the treatment of poststroke central neuropathic pain

目的探究普瑞巴林在脑卒中后中枢神经痛治疗中的临床应用效果。方法回顾性选择2017年8月至2019年8月佛山市第一人民医院神经科收治的使用普瑞巴林的脑卒中后中枢神经痛患者40例为治疗组,选择同期使用奥卡西平的脑卒中后神经痛患者30例作为对照组。两组均予以脑卒中规范化治疗,均治疗观察8周。比较两组治疗前后疼痛、心理健康状况变化情况以及药物不良反应发生率。结果治疗前两组患者的平均每日疼痛评分量表分值(DPRS)比较,差异无统计学意义(P>0.05),治疗4、8周后,治疗组的DPRS分值明显低于对照组(P<0.05)。治疗8周后,治疗组患者的焦虑(HAMA)、抑郁(HAMD)评分明显低于对照组(P<0.05)。治疗组的药物不良反应总发生率为5.26%,与对照组的2.63%比较,差异无统计学意义(P>0.05)。结论普瑞巴林能够显著减轻脑卒中后中枢神经痛患者的疼痛感,并有助于消除不良情绪,且不会增加不良反应发生。

Objective To investigate the clinical application efficacy of pregabalin in the treatment of post-stroke central neuropathic pain.Methods Patients with post-stroke central neuropathic pain treated with pregabalin and admitted to the department of neurology of the First People's Hospital of Foshan from August 2017 to August 2019 were retrospectively selected as the treatment group(n=40),and patients with post-stroke central neuropathic pain treated with oxcarbazepine in the same period were selected as the control group(n=30).Both groups were all given standardized treatment for stroke,and the treatment was observed for 8 weeks.The changes of pain,mental health and the incidence of adverse drug reactions were compared between the two groups before and after treatment.Results Before treatment,there was no statistically significant difference in the average daily pain rating scale(DPRS)between the two groups of patients(P>0.05).After 4 weeks and 8 weeks of treatment,the DPRS score of the treatment group was significantly lower than that of the control group(P<0.05).After 8 weeks of treatment,the scores of anxiety(Hamilton anxietyscale,HAMA)and depression(Hamilton depressive scale,HAMD)in the treatment group were significantly lower than those in the control group(P<0.05).The incidence of adverse drug reactions in the treatment group was 5.26%,which was not significantly different from 2.63%in the control group,without statistically significant difference(P>0.05).Conclusion Pregabalin can significantly reduce the post-stroke central neuropathic pain of patients and is conducive to eliminating adverse emotions without increasing the incidence of adverse reactions.